Come back later: ODAC rejects accelerated approval of neoadjuvant Keytruda in TNBC

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

In a unanimous vote, the FDA Oncologic Drugs Advisory Committee recommended against an accelerated approval for Keytruda for patients with high-risk, early-stage triple-negative breast cancer, in combination with chemotherapy as neoadjuvant treatment, then as a single agent as adjuvant treatment after surgery.

The company was seeking approval based on the surrogate endpoint of pathologic complete response.

The advisory committee’s recommendation—reached in a 10:0 vote with no abstentions at the Feb. 9 meeting—was to defer any approval decision until more mature data from the company’s ongoing clinical trial are available.

In an odd regulatory/linguistic twist, a Yes vote indicating “Yes, defer,” amounted to a “No, do not approve.”

“In the couple of years that I’ve been on the ODAC, this is the first time that I’ve encountered a voting question that basically said, should we defer this, as opposed to the Yes or No. Has the efficacy and safety been demonstrated, so Yes or No, we should approve,” ODAC Chair Philip C. Hoffman, professor of medicine at the University of Chicago Section of Hematology/Oncology Department of Medicine, said after the votes were cast.

To access this subscriber-only content please log in or renew your subscription.

Looking for IP Login? Our IP Login system is now automatic. If your institution has a site license, please log in from on site or via your VPN to access this content.

Login Subscribe
Paul Goldberg
Editor & Publisher
Table of Contents

YOU MAY BE INTERESTED IN

When conducting a randomized clinical trial of a treatment regimen based on an immune checkpoint inhibitor, trial sponsors should include overall survival as an endpoint, FDA officials say.
Paul Goldberg
Editor & Publisher

Login